Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/31663
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 17775/20116 (88%)
造訪人次 : 8989692      線上人數 : 433
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: http://ir.cnu.edu.tw/handle/310902800/31663


    標題: Clinical benefits of antimicrobial de-escalation in adults with community-onset monomicrobial Escherichia coli, Klebsiella species and Proteus mirabilis bacteremia
    作者: Lee, Ching-Chi
    Wang, Jiun-Ling
    Lee, Chung-Hsun
    Hung, Yuan-Pin
    Hong, Ming-Yuan
    Tang, Hung-Jen
    Ko, Wen-Chien
    貢獻者: Madou Sin Lau Hosp, Dept Internal Med, Div Crit Care Med
    Chang Jung Christian Univ, Coll Hlth Sci, Grad Inst Med Sci
    Natl Cheng Kung Univ,Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med
    Natl Cheng Kung Univ, Coll Med, Dept Med
    Natl Cheng Kung Univ Hosp, Dept Emergency Med
    Tainan Hosp, Minist Hlth & Welf, Dept Internal Med
    Chi Mei Med Ctr, Dept Med
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    關鍵字: De-escalation
    Bacteremia
    Escherichia coli
    Klebsiella species
    Proteus mirabilis
    日期: 2017-09
    上傳時間: 2018-11-30 15:52:01 (UTC+8)
    出版者: Elsevier Science Bv
    摘要: The clinical benefits of an antimicrobial de-escalation strategy were compared with those of a noswitch strategy in bacteremic patients. Adults with community-onset monomicrobial Escherichia coli, Klebsiella species and Proteus mirabilis bacteremia treated empirically using broad-spectrum betalactams, including third-generation cephalosporins (GCs), fourth-GC or carbapenems, were treated definitively with first-or second-GCs (de-escalation group), the same regimens as empirical antibiotics (no-switch group), or antibiotics with a broader-spectrum than empirical antibiotics (escalation group). The eligible 454 adults were categorized as the de-escalation (231 patients, 50.9%), no-switch (177, 39.0%), and escalation (46, 10.1%) groups. Patients with de-escalation therapy were more often female, had less critical illness and fatal comorbidity, and had a higher survival rate than patients in the other two groups. After propensity score matching in the de-escalation and no-switch groups, critical illness at onset (Pitt bacteremia score = 4; 16.5% vs. 12.7%; P = 0.34) or day 3 (2.5% vs. 2.5%; P = 1.00), fatal comorbidity (16.5% vs. 21.5%; P = 0.25), time to defervescence (4.6 vs. 4.7 days; P = 0.89), hospital stays (11.5 vs. 10.3 days; P = 0.13) and 4-week crude mortality rate (4.4% vs. 4.4%; P = 1.00) were similar. However, lower antibiotic cost (mean: 212.1 vs. 395.6 US$, P < 0.001) and fewer complications of bloodstream infections due to resistant pathogens (0% vs. 5.1%, P = 0.004) were observed in the de-escalation group. De-escalation to narrower-spectrum cephalosporins is safe and cost-effective for adults with community-onset EKP bacteremia stabilized by empirical broad-spectrum beta-lactams. (C) 2017 Elsevier B. V. and International Society of Chemotherapy. All rights reserved.
    關聯: International Journal of Antimicrobial Agents, v.50, n.3, pp.371-376
    顯示於類別:[保健營養系(所) ] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML225檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋